Published in Anticancer Res on March 12, 2004
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer (2005) 1.02
Carcinoma of Unknown Primary - an Orphan Disease? Breast Care (Basel) (2008) 0.85
Metabolic phenotypes in primary unknown metastatic carcinoma. J Transl Med (2014) 0.76
Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary). BMC Cancer (2007) 0.75
Unknown primary adenocarcinomas: a single-center experience. Bosn J Basic Med Sci (2016) 0.75
Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer (2017) 0.75
Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol (2017) 0.75
Angiogenesis in unknown primary tumors. Clin Exp Med (2011) 0.75
Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol (2006) 0.75
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol (2011) 3.43
Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis (2008) 2.89
Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed (2006) 2.57
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett (2006) 1.98
Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology (2005) 1.94
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 1.76
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett (2007) 1.61
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol (2013) 1.53
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Isolation of endothelial cells from fresh tissues. Nat Protoc (2008) 1.49
Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst (2004) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta (2010) 1.38
Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem (2008) 1.37
Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis (2008) 1.37
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res (2003) 1.37
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol (2008) 1.33
Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer (2010) 1.31
Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond) (2007) 1.28
Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab (2004) 1.28
Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res (2004) 1.24
Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood (2007) 1.24
Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano (2011) 1.23
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res (2003) 1.22
RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J (2010) 1.21
Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res (2007) 1.20
Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett (2010) 1.16
Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials (2009) 1.15
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer (2005) 1.13
The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta (2010) 1.12
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res (2006) 1.11
Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed (2006) 1.11
Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta (2006) 1.11
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J (2002) 1.09
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother (2007) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem (2004) 1.06
Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol (2006) 1.05
Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis (2010) 1.05
Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther (2006) 1.04
NF-kappa B: a new player in angiostatic therapy. Angiogenesis (2008) 1.04
Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett (2003) 1.03
Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst (2006) 1.03
Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem (2003) 1.02
Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res (2007) 1.01
Angiostatic activity of the antitumor cytokine interleukin-21. Blood (2008) 0.98
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res (2011) 0.98
Imbalance of angiopoietin-1 and angiopoetin-2 in severe dengue and relationship with thrombocytopenia, endothelial activation, and vascular stability. Am J Trop Med Hyg (2012) 0.98
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis (2010) 0.97
Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med (2012) 0.97
Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun (2007) 0.96
CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis (2012) 0.96
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol (2013) 0.95
Effects of radiotherapy and chemotherapy on angiogenesis and leukocyte infiltration in rectal cancer. Int J Radiat Oncol Biol Phys (2006) 0.95
MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochim Biophys Acta (2009) 0.95
Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat (2012) 0.95
Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev (2013) 0.95
Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta (2013) 0.93
Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res (2004) 0.93
Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release (2011) 0.92
Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology (2013) 0.92
Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia (2008) 0.92
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med (2012) 0.91
Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril (2005) 0.91
A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors. Biochem Biophys Res Commun (2008) 0.91
In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochim Biophys Acta (2005) 0.90
Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiother Oncol (2013) 0.89
Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J (2003) 0.89
Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem (2011) 0.89
Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer (2003) 0.89
Tumor endothelium is characterized by a matrix remodeling signature. Front Biosci (Schol Ed) (2009) 0.88
ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells. Cancer Res (2010) 0.88
Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem (2007) 0.87
Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J Immunol (2010) 0.87
Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB (Oxford) (2013) 0.87
Angiogenesis inhibition for the improvement of photodynamic therapy: the revival of a promising idea. Biochim Biophys Acta (2012) 0.86
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med (2014) 0.86
Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res (2006) 0.85
NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol Cancer Ther (2009) 0.85
Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging. Neoplasia (2012) 0.85
The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J Biol Chem (2011) 0.84
Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun (2006) 0.84
Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun (2007) 0.84
MRI after chemoradiotherapy of rectal cancer: a useful tool to select patients for local excision. Dis Colon Rectum (2010) 0.84
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis (2015) 0.84
Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis (2010) 0.84
Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis (2003) 0.83